<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822341</url>
  </required_header>
  <id_info>
    <org_study_id>TG-0054-01</org_study_id>
    <nct_id>NCT00822341</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending Single Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TG-0054 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiGen Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TaiGen Biotechnology Co., Ltd.</source>
  <brief_summary>
    <textblock>
      TG-0054 is a CXCR4 antagonist with stem cell mobilization effect as proven in animal model,
      this is the fist in human study to investigator the safety, tolerability and PK/PD in healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability for a single IV dose of TG-0054</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) of TG-0054</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the plasma pharmacokinetics (PK) profile of TG-0054</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacodynamic (PD) effects of TG-0054 via CD34+stem cell, CD133+ progenitor cell counts; white blood cell (WBC), red blood cell (RBC), platelet, and differential counts</measure>
  </secondary_outcome>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG-0054</intervention_name>
    <description>0.1, 0.2, 0.4, 0.8, 1.6, and 3.2 mg/kg of TG-0054/placebo via 15 min IV infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female 18 to 45 years of age inclusive

          -  Body mass index (BMI) in the range of 19.0 to 30.0 kg/m² and body weight ≥ 50 kg
             inclusive

          -  Good physical and mental health status determined on the basis of the medical history
             and a general clinical examination

          -  Subjects must have used a consistent form of acceptable oral birth control or the
             double barrier method (intrauterine device (IUD) plus condom, spermicidal gel plus
             condom) for at least 3 months prior to study initiation

        Exclusion Criteria:

          -  Any medical condition (other than a self-limited illness) that requires ongoing and
             current medical attention

          -  History of any other hematologic disorders including thromboembolic disease or anemia

          -  Severe trauma, fracture, major surgery, or biopsy of a parenchymal organ within the
             past 3 months

          -  Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent

          -  Subjects who currently smoke (intake nicotine or nicotine-containing products) or have
             given up smoking for less than 6 months before the first administration of study drug

          -  Subjects who are carriers of the Hepatitis B surface antigen (HBsAg) or Hepatitis C
             antibody or who are Human Immunodeficiency Virus (HIV) antibody positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Goldwater, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Clinical Pharmacology Research Unit Harbor Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL Clinical Pharmacology Research Unit Harbor Hospital Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2014</last_update_posted>
  <responsible_party>
    <name_title>Hao Zhang M.D, Medical Director</name_title>
    <organization>TaiGen Biotechnology Co., Ltd.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

